Dealmaking Pays Off For Allergan As Revenue Rises 124% In 2015

Allergan PLC's dealmaking ways paid off in 2015 as revenue rose 124% to $15.1bn and non-GAAP earnings per share grew 78% to $13.43, thanks in large part to Actavis PLC's $66bn acquisition of Botox (onabotulinumtoxinA) maker Allergan Inc. last year and other recent transactions.